Dichloropane

# Research Output: Dichloropane (RTI-111)

**Provenance ID:** c39d9fbc-3bdd-4f85-929c-b2700adacc2c  
**Research date:** 2026-05-11  
**Substance:** Dichloropane | Slug: dichloropane | PSX ID: PSX-0160

---

## Chemical Identity

### Verified Data (PubChem CID 127024 / NCATS FDA UNII V7SQE82R87)

| Field | Value | Source |
|---|---|---|
| IUPAC name | methyl (1R,2S,3S,5S)-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane-2-carboxylate | PubChem [Ref 10] |
| Molecular formula | C₁₅H₁₇Cl₂NO₂ | PubChem, NCATS [Ref 10] |
| Molecular weight | 314.2 g/mol | PubChem, NCATS [Ref 10] |
| InChIKey | JFUNLJPTPCQLIR-PJQZNRQZSA-N | PubChem, NCATS [Ref 10] |
| CAS number | 146725-34-0 | NCATS, ChemicalBook [Ref 25] |
| PubChem CID | 127024 | PubChem [Ref 10] |
| FDA UNII | V7SQE82R87 | NCATS [Ref 10] |
| EPA CompTox | DTXSID20932894 | NCATS [Ref 10] |
| pKa (predicted) | 9.70 | ChemicalBook [Ref 25] |
| Boiling point (predicted) | 407.6 ± 45.0 °C | ChemicalBook [Ref 25] |
| Density (predicted) | 1.284 ± 0.06 g/cm³ | ChemicalBook [Ref 25] |
| Physical appearance | White powder | Vendor data (web-retrieved) |

The brief's systematic name ("methyl (1R,2S,3S,5S)-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane-2-carboxylate") matches PubChem CID 127024 exactly. The brief is missing SMILES, molecular formula, molecular weight, and InChIKey — these are now confirmed above. The SMILES from NCATS is: `[C@@H]1([C@H]2CC[C@@H](C[C@@H]1C3=CC=C(Cl)C(Cl)=C3)N2)C(=O)OC` (note: missing N-methyl, consistent with nortropane structure).

### ⚠️ CRITICAL STRUCTURAL DISCREPANCY — FLAG FOR HUMAN REVIEW

Two distinct molecular entities are sold under the name "dichloropane" / "RTI-111":

1. **CAS 146725-34-0** — Nortropane (secondary amine, no N-methyl group): C₁₅H₁₇Cl₂NO₂, MW 314.2. IUPAC: methyl (1R,2S,3S,5S)-3-(3,4-dichlorophenyl)-**8-azabicyclo[3.2.1]octane**-2-carboxylate. Confirmed by PubChem CID 127024, NCATS FDA UNII V7SQE82R87, ChemicalBook. This is the compound as described in the brief.

2. **CAS 150653-91-1** — N-methyl tropane hydrochloride salt (tertiary amine, N-methyl group present): C₁₆H₁₉Cl₂NO₂ · HCl, MW 364.7. PubChem CID 9797476 (free base: C₁₆H₁₉Cl₂NO₂, MW 328.2, InChIKey AMIHUYQKNJHXPT-DRABBMOASA-N). This is sold by BenchChem and Smolecule as "RTI-111." [Ref 24]

The original Meltzer 1993 synthesis paper (PMID 8464040) refers to the compound as "3β-(3,4-dichlorophenyl)tropane-2β-carboxylic acid methyl ester" — the word "tropane" in classical nomenclature implies the N-methyl compound (CAS 150653-91-1). However, the NCATS/PubChem authoritative database assigns the name "dichloropane" to the nortropane (CAS 146725-34-0), and the IC50 values at NCATS are consistent with the nortropane showing elevated SERT/NET affinity from N-demethylation (per Boja et al. 1994 [Ref 12]).

**This ambiguity must be resolved by a pharmacology editor before the article can accurately describe the compound's molecular structure.** The brief's seed data (formula empty, no SMILES) is consistent with this confusion being pre-existing in the database.

**PsychonautWiki IUPAC discrepancy:** PsychonautWiki lists the IUPAC as "Methyl (2S,3S)-3-(3,4-dichlorophenyl)-**8-methyl-8-azabicyclo[3.2.1]octane**-2-carboxylate" (N-methyl tropane), which contradicts PubChem/NCATS. [Ref 20]

---

## Pharmacology

### Mechanism of Action

Dichloropane acts as a potent serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI / triple reuptake inhibitor), simultaneously blocking the dopamine transporter (DAT), serotonin transporter (SERT), and norepinephrine transporter (NET) [Ref 10, 11]. This prevents monoamine recycling, increasing synaptic concentrations of dopamine, serotonin, and norepinephrine.

Unlike cocaine, dichloropane does not possess local anesthetic activity, as it does not block sodium channels [Ref 20]. It shares cocaine's monoamine reuptake inhibition mechanism but is pharmacologically distinct in its transporter selectivity profile, with substantially higher relative affinity for SERT and NET than cocaine [Ref 10].

### Binding Affinity Data (In Vitro)

The following IC50 values are reported in NCATS Inxight Drugs (FDA), attributed to the Meltzer 1993 primary synthesis paper [Ref 11]:

| Transporter | IC50 | Notes |
|---|---|---|
| DAT (dopamine transporter) | **0.79 nM** | Most potent of the three targets |
| SERT (serotonin transporter) | **3.13 nM** | ~4× less potent than at DAT |
| NET (norepinephrine transporter) | **18 nM** | ~23× less potent than at DAT |

**Source note:** The IC50 values are sourced from NCATS [Ref 10] and are consistent with the nortropane form of the compound; these values have not been independently confirmed from a PubMed-accessible abstract. The Meltzer 1993 paper (PMID 8464040) is the most likely primary source [Ref 11]. Verification against full text is recommended.

For comparison: cocaine has DAT IC50 ~270 nM, SERT IC50 ~2,000 nM, NET IC50 ~1,000 nM — dichloropane is roughly 300–600× more potent at DAT than cocaine. This makes it "one of the most potent cocaine congeners yet reported" per the 1993 synthesis paper (Meltzer et al. [Ref 11]).

The Zou et al. 2003 SAR study (PMID 12825932 [Ref 5]) confirmed that (R)-2β-substituted 3β-(3,4-dichlorophenyl)tropane scaffolds bind DAT with Ki = 5.5–100 nM depending on 2-position substitution, with the methyl ester compound (dichloropane) in the high-affinity range.

The Carroll et al. 2005 synthesis paper (PMID 15828814 [Ref 6]) examined 3β-(3',4'-disubstituted phenyl)tropane-2β-carboxylic acid methyl esters and reported subnanomolar IC50 values at both DAT and SERT for most compounds with 3',4'-disubstitution.

The Boja et al. 1994 paper (PMID 8164265 [Ref 12]) established the pharmacological principle that N-demethylation (producing the secondary amine / nortropane form) causes **4–19-fold enhancement of SERT affinity** and **2–44-fold enhancement of NET affinity** with minimal change at DAT, compared to the N-methyl tropane parent. This is mechanistically consistent with dichloropane (if it is the nortropane CAS 146725-34-0) having higher SERT/NET activity than a DAT-selective N-methyl analog would.

### In Vivo Pharmacology (Animal Data)

**PET imaging ([¹¹C]-CDCT):** Brownell et al. 1996 (PMID 8965196 [Ref 9]) evaluated radiolabeled dichloropane as a PET probe for dopamine terminals. In control monkeys, caudate specific binding ratio was 2.3 ± 0.4 and putamen 2.4 ± 0.5 at 60 minutes. Despite having the **highest DAT affinity** among three phenyltropane comparators, dichloropane produced the **lowest specific binding ratios**, likely because its substantial SERT affinity (IC50 3.13 nM) causes significant off-target accumulation in serotonin-rich regions including the thalamus. This rendered it less useful as a selective DAT imaging agent compared to [¹¹C]-CFT (WIN 35,428). [Ref 9, 23]

**Onset and duration:** In animal studies, dichloropane exhibits a slower onset and longer duration of action compared to cocaine [Ref 20]. This pharmacokinetic property is a class characteristic of RTI phenyltropane compounds and is mechanistically attributed to their higher DAT binding affinity creating "persistent binding" compared to cocaine's faster off-rate.

**Behavioral stimulant effects:** The rate of onset at DAT is a key determinant of stimulant and reinforcing effects in the RTI series. Kimmel et al. 2007 (PMID 17258302 [Ref 17]) demonstrated in squirrel monkeys that RTI-112 (3'-methyl-4'-chlorophenyl, the structurally closest published analog to dichloropane in this series) **failed to produce behavioral stimulant effects** due to its slower onset and nonselective monoamine transporter profile. Similarly, faster-onset, DAT-selective compounds showed stronger stimulant and reinforcing effects. Dichloropane's similarly nonselective profile (SERT IC50 3.13 nM) may attenuate or modify its stimulant character vs. cocaine.

**Self-administration and discriminative stimulus:** Ranaldi et al. 2000 (PMID 11255920 [Ref 3]) directly studied RTI-111 (dichloropane) in rhesus monkeys for reinforcing and discriminative stimulus effects and its interaction with methamphetamine. Cook et al. 2001 (PMID 11797070 [Ref 4]) found cocaine-like discriminative stimulus effects in rats for phenyltropane analogs in this series.

**Reinforcing efficacy:** The RTI phenyltropane class generally shows lower reinforcing strength than cocaine, attributed to slower onset of DAT occupancy (Wee et al. 2006, PMID 15957006 [Ref 8]; Czoty et al. 2010, PMID 20580733 [Ref 15]; Kimmel et al. 2008, PMID 18468667 [Ref 16]). However, faster-onset analogs in this series did maintain robust self-administration. The specific self-administration profile of dichloropane (RTI-111) vs. cocaine was studied in rhesus monkeys (Ranaldi 2000 [Ref 3]).

### Pharmacokinetics

No human pharmacokinetic studies have been published for dichloropane. Animal data indicate slower CNS uptake than cocaine, consistent with higher lipophilicity and binding affinity causing prolonged tissue association.

**Metabolism (inferred from class):** Cocaine analogs with a methyl ester at the 2β position are metabolized by plasma/hepatic cholinesterases and CYP3A4 to the carboxylic acid (nor-) metabolite via ester hydrolysis. The Freiburg forensic poster (Grumann 2017 [Ref — web-retrieved]) detected ester hydrolysis metabolite and a possible N-demethylation metabolite in human samples (blood ~1.0 ng/mL, urine ~4.5 ng/mL in forensic cases). The brief's stated half-life of 3 days is not sourced from published literature and is flagged (see Gaps & Flags).

No published CYP enzyme involvement data specific to dichloropane was found.

---

## History

**Discovery and synthesis (1993):** Dichloropane was first synthesized and characterized by Meltzer PC, Liang AY, Brownell AL, Elmaleh DR, and Madras BK (Massachusetts General Hospital / Harvard Medical School), published in the *Journal of Medicinal Chemistry* in 1993 (PMID 8464040 [Ref 11]). The paper evaluated several analogs of 3β-phenyltropane-2β-carboxylic acid methyl ester as inhibitors of cocaine binding to primate caudate-putamen and described dichloropane (then called "3β-(3,4-dichlorophenyl)tropane-2β-carboxylic acid methyl ester") as **"one of the most potent cocaine congeners yet reported."**

**RTI designation:** The compound was subsequently studied at Research Triangle Institute (RTI International, North Carolina) by F. Ivy Carroll, Michael Kuhar, and colleagues as part of their RTI-series phenyltropane program investigating potential cocaine pharmacotherapies. It was designated RTI-111 in this program. The alternative name O-401 is also used (confirmed in Vermont regulations [Ref 19]).

**Research context:** The RTI phenyltropane program, active from the early 1990s through the 2010s, synthesized hundreds of cocaine analogs seeking a safe, long-acting, low-abuse-potential substitute for cocaine addiction treatment — analogous to methadone for opioids or nicotine replacement for smoking. RTI-111 (dichloropane) was studied preclinically but was not selected for clinical development; RTI-336 was the lead candidate from this program (Carroll et al. 2006 [Ref 7]).

**Research chemical market:** Dichloropane first appeared on the online research chemical market approximately around 2010, reportedly among the first cocaine analogs available in this context [Ref 20].

**EMCDDA notification (2016):** The first forensic seizure of dichloropane was reported to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) in late 2016 by the Swedish police. A second sample was collected by the Slovenian National Forensic Laboratory in the same year. The EMCDDA issued a formal early warning notification (EU-EWS-RCS-FN-2016 0065) [Ref 20, 19].

**Analytical methods (2019):** Sorribes-Soriano et al. 2019 (PMID 31262514 [Ref 18]) published a validated MEPS-IMS method for dichloropane detection in oral fluids (saliva), with LOD 30 µg/L.

---

## Subjective Effects

No controlled human administration studies have been published for dichloropane. The subjective effects profile is inferred from:
- Animal behavioral pharmacology (discriminative stimulus and self-administration data)
- Structural analogy to cocaine and other phenyltropane stimulants
- Limited community/user reports [Ref 20]

**Published animal-model findings:**
- Cocaine-like discriminative stimulus effects in rats and rhesus monkeys (Cook 2001 [Ref 4]; Ranaldi 2000 [Ref 3])
- Stimulant (locomotor activating) effects expected but possibly attenuated by slower onset vs. cocaine (Kimmel 2007 [Ref 17])
- Positive reinforcer in rhesus monkey self-administration models [Ref 3]

**Onset and duration (seed data from DB — community-sourced, not from controlled studies):**
- **Smoked:** onset 15–60 seconds, come-up 15–60 seconds, peak 15–30 minutes, offset 20–40 minutes, total 40–75 minutes
- **Insufflated:** onset 15–30 minutes, come-up 15–30 minutes, peak 60–90 minutes, offset 60–90 minutes, total 2–4 hours

These durations are consistent with the animal-model finding of longer duration vs. cocaine, and with the route-dependent absorption kinetics of insufflated vs. smoked cocaine analogs. **The dose and duration data should be flagged as community-sourced** — no controlled human studies underpin these values.

**Effect character (class inference):** As an SNDRI, dichloropane would produce stimulant-class effects mediated by increased monoamine tone: euphoria, stimulation, arousal, appetite suppression, thought acceleration, and increased motivation. The elevated SERT component (relative to cocaine) may add entactogen-adjacent qualities (compared to pure DAT-selective stimulants). No published controlled subjective-effects studies exist.

---

## Safety & Toxicity

### Human Data
**No published human safety or toxicity studies exist for dichloropane.** This is an emerging substance with very limited recreational use history [Ref 20].

**Forensic case data (limited):** The Freiburg forensic conference poster (Grumann 2017, web-retrieved [Ref — not in registry as not peer-reviewed]) reported three human forensic cases positive for RTI-111. One case showed approximately 1.0 ng/mL RTI-111 in femoral blood and approximately 4.5 ng/mL in urine. Metabolites detected included the ester hydrolysis product. No fatalities attributable directly to dichloropane were identified in the available literature.

**Note:** The brief states "Inferred from pharmacological class — not sourced from literature. Review recommended." for toxicity data. This flag is appropriate and is confirmed by this research.

### Animal Data / Class Inference

As a potent SNDRI and cocaine analog:
- **Cardiovascular risks** (tachycardia, hypertension, vasoconstriction) are expected from elevated catecholamine tone; these are consistent with the seeded effects (vasoconstriction, abnormal heartbeat) [Ref 10]
- **Hyperthermia** is a documented risk with stimulants that block dopamine and serotonin reuptake simultaneously
- **Seizure risk** is elevated with powerful stimulants, including cocaine analogs
- **No LD50 data** for dichloropane found in published literature
- **No published organ toxicity studies** specific to dichloropane

### Abuse Potential

The RTI series phenyltropane literature consistently shows:
1. Slower-onset analogs have reduced reinforcing strength vs. cocaine (Wee 2006 [Ref 8]; Kimmel 2007 [Ref 17]; Czoty 2010 [Ref 15])
2. But these compounds DO function as positive reinforcers and DO produce cocaine-like discriminative stimulus effects [Ref 3, 4]
3. Non-DAT-selective analogs (like the structurally similar RTI-112) may have lower abuse potential than DAT-selective compounds, but the relationship is not simple [Ref 17]

Dichloropane is classified as having a "moderately addictive with high potential for abuse" in the brief seed data. This appears to be class-inferred rather than substance-specific and should be flagged as unverified.

---

## Harm Reduction

No published harm reduction guidelines specific to dichloropane exist. Recommendations must be extrapolated from the general stimulant and cocaine analog literature:

1. **Start low:** No human dose-response data exists; individual sensitivity is unknown
2. **Avoid MAOI combinations:** Risk of serotonin syndrome due to SERT inhibition; potentially fatal
3. **Avoid with other stimulants:** Additive cardiovascular strain (hypertension, tachycardia)
4. **Cardiovascular monitoring:** Extended duration of action (vs. cocaine) means cardiovascular stress persists longer
5. **Hydration:** Stimulant-class dehydration risk; avoid overhydration
6. **Temperature regulation:** Risk of hyperthermia in hot environments or with physical exertion
7. **Testing:** Reagent testing; dichloropane is not reliably distinguished from other stimulants by standard Marquis/Mecke reagents — more specific analytical methods required (Sorribes-Soriano 2019 [Ref 18])

**⚠️ FLAG:** The brief's toxicity notes state values are "inferred from pharmacological class — not sourced from literature. Review recommended." This is confirmed and should be disclosed prominently in the article.

---

## Tolerance & Dependence

**No substance-specific human or animal tolerance/dependence studies for dichloropane were found in published literature.**

The brief seed data states:
- Tolerance buildup: "with prolonged and repeated use"
- Half-life: 3 days
- Full reset: 1.25 weeks
- Cross-tolerances: dopamine, stimulant

These values appear to be extrapolated from general stimulant/cocaine pharmacology, not from dichloropane-specific studies. **Flagged as unverified.**

**Mechanism (class inference):** Tolerance to cocaine-class DAT inhibitors is mediated by dopaminergic downregulation (D2/D3 receptor downregulation, DAT upregulation). The RTI phenyltropane series was notably studied for lack of sensitization in some animal models (Carroll 2006 [Ref 7]), which may indicate a different tolerance trajectory than cocaine — but no dichloropane-specific data was found.

The elevated SERT component of dichloropane's profile means that SERT downregulation (similar to that seen with SSRI use) may also contribute to tolerance with prolonged use, with corresponding implications for mood and anxiety upon cessation.

---

## Interactions

No published drug interaction studies specific to dichloropane exist. The following interactions are inferred from dichloropane's pharmacological mechanism (SNDRI) and apply broadly to this class:

| Interaction | Mechanism | Severity | Evidence Level |
|---|---|---|---|
| MAOIs (phenelzine, tranylcypromine, selegiline, etc.) | Combined SERT inhibition + MAO inhibition → serotonin accumulation → serotonin syndrome | **HIGH — potentially fatal** | Class-level clinical evidence |
| SSRIs (fluoxetine, sertraline, etc.) | Additive serotonin reuptake inhibition; serotonin syndrome risk | **HIGH** | Class-level |
| SNRIs (venlafaxine, duloxetine) | Additive SERT + NET inhibition | **HIGH** | Class-level |
| Other stimulants (amphetamines, methylphenidate, cathinones) | Additive DAT/NET inhibition; additive cardiovascular strain | **MODERATE–HIGH** | Class-level |
| Alcohol | CNS depressant masks stimulant effects; possible cardiovascular interaction | **MODERATE** | General stimulant class |
| Cocaine | Additive DAT/SERT/NET inhibition; additive cardiovascular stress | **HIGH** | Class-level |
| Antihypertensives | Stimulant-mediated hypertension may blunt drug effect | **MODERATE** | Class-level |

**⚠️ Safety-critical flag:** All interaction severity ratings above are class-inferred, not specific to dichloropane. No published interaction studies exist for this compound.

---

## Legal Status

| Jurisdiction | Status | Notes |
|---|---|---|
| **United States (federal)** | Not explicitly scheduled | Subject to Federal Analogue Act (21 U.S.C. § 813) as structural analog of cocaine (Schedule II); intent for human consumption required for prosecution |
| **United States (Vermont)** | Explicitly regulated | Listed in Vermont Code of Regulations 13-140-011-X, Section 7.0 Regulated Drugs, as "Dichloropane; RTI-111; 0-401" [Ref 19] |
| **United Kingdom** | Covered | UK Psychoactive Substances Act 2016 (blanket ban on all psychoactive substances not otherwise exempted); no specific scheduling under Misuse of Drugs Act 1971 found |
| **European Union** | EMCDDA early warning (2016) | Formal notification EU-EWS-RCS-FN-2016 0065; no EU-wide scheduling confirmed; member state law varies [Ref 20] |
| **Sweden** | Likely controlled | Site of first seizure reported to EMCDDA (late 2016); Swedish NPS legislation likely applies |
| **Slovenia** | Likely controlled | Second 2016 seizure; NPS legislation likely applies |
| **Canada** | Unclear — likely analogue provision | Not explicitly named in Controlled Drugs and Substances Act; may fall under analogue provisions |
| **Australia** | Unclear | Not found in national Poisons Standard; Victorian Drugs Act Part IIIA (2017) covers psychoactive substances commercially; Commonwealth 2015 psychoactive substances amendments may apply |

**Note:** Vermont's categorization of dichloropane under "Hallucinogenic Drugs; Synthetic Cannabinoids; Tryptamines; Cannabimimetics; Mescaline Analogs; Dissociatives" is a misclassification — dichloropane is a stimulant/SNDRI with no hallucinogenic or dissociative mechanism. This appears to be a regulatory error in Vermont's classification scheme, not a pharmacological statement. [Ref 19]

---

## Clinical Trials

No clinical trials for dichloropane (RTI-111) were found on ClinicalTrials.gov. A search for "dichloropane RTI-111 cocaine dopamine transporter" returned zero results.

Dichloropane was studied as part of the RTI International preclinical phenyltropane program for cocaine addiction pharmacotherapy but was not selected for clinical development. RTI-336 was chosen as the lead compound for that program instead (Carroll et al. 2006 [Ref 7]).

---

## Community Feedback Analysis

No community feedback was submitted for Part A2 of the brief. Section skipped per instructions.

---

## Gaps & Flags

### Safety-Critical — Require Human Review

1. **⚠️ STRUCTURAL IDENTITY AMBIGUITY:** Two CAS numbers (146725-34-0 = nortropane; 150653-91-1 = N-methyl tropane HCl) are both marketed as "dichloropane/RTI-111." The brief's systematic name matches the nortropane (CAS 146725-34-0), but some published research and vendor descriptions use "tropane" terminology implying the N-methyl form. The molecular formula, SMILES, and InChIKey in the database are empty — these must be resolved to a single confirmed identity before article generation. Recommendation: Adopt PubChem CID 127024 / NCATS UNII V7SQE82R87 (nortropane, CAS 146725-34-0) as canonical.

2. **⚠️ IC50 VALUES NOT VERIFIED FROM PRIMARY SOURCE ABSTRACT:** The binding affinities (DAT 0.79 nM, SERT 3.13 nM, NET 18 nM) are sourced from NCATS Inxight Drugs database which attributes them to primary literature. These values could not be confirmed from an accessible PubMed abstract. The most likely primary source is Meltzer et al. 1993 (PMID 8464040 [Ref 11]). Full-text access required for definitive confirmation.

3. **⚠️ DOSE/DURATION DATA NOT FROM CONTROLLED STUDIES:** All dose ranges and duration data in the brief seed data are community-sourced with no published pharmacology studies supporting them. Flagged for article disclosure.

4. **⚠️ TOXICITY DATA INFERRED:** Brief states "Inferred from pharmacological class — not sourced from literature. Review recommended." Confirmed: no substance-specific toxicity studies published. Acute/chronic toxicity, LD50, and organ-specific effects are all class-inferred.

5. **⚠️ TOLERANCE/DEPENDENCE VALUES UNVERIFIED:** Half-life of 3 days and cross-tolerance values in seed data are not sourced from published dichloropane-specific studies.

6. **⚠️ INTERACTION SEVERITY RATINGS:** All listed interaction severities are class-inferred (SNDRI class), not dichloropane-specific. No dichloropane interaction studies exist.

### Data Gaps (Non-Safety-Critical)

7. **No human pharmacokinetics:** No studies on bioavailability, Tmax, half-life, or CYP enzyme involvement in humans or non-human primates specifically for dichloropane.

8. **No clinical trials:** Zero results on ClinicalTrials.gov.

9. **No published case reports of adverse events or overdose:** Limited to a forensic conference poster (Grumann 2017, not peer-reviewed) with three human forensic cases.

10. **Onset/duration for insufflated route:** No pharmacokinetic modeling data; insufflated duration (2–4 hours total) appears to be extrapolated from cocaine class pharmacology.

11. **Legal status of Canada and Australia:** Not resolved from available sources; "likely covered by analogue provisions" only.

12. **Vermont misclassification:** Vermont places dichloropane in the "Hallucinogenic" category rather than stimulant — this should be noted as a regulatory classification error in any legal status section.

13. **No melting point data:** Predicted values only; no experimental melting point found in literature.

14. **Physical properties:** Only predicted values available (BP, density, pKa). Solubility data not found.

15. **Original RTI-111 behavioral study data:** Full abstract text for Ranaldi et al. 2000 (PMID 11255920) does not contain specific dose, endpoint, or quantitative behavioral data due to truncated abstract. Full text recommended.

16. **Meltzer 1993 full text:** The abstract (PMID 8464040) confirms synthesis and high binding affinity but does not provide specific IC50 values. Full text access required to confirm the 0.79 nM DAT IC50 value.